X4 Pharma's CEO on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications
Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4 will have in chronic neutropenia towards the end of the month.